|
||
|
Nventa Biopharmaceuticals Corporation
Download PDF Members: Nventa Biopharmaceuticals Corporation (TSX:NVN) is developing innovative therapeutics for the treatment of viral infections, with a focus on diseases caused by the human papillomavirus (HPV). Our lead therapeutic candidate is HspE7, a novel therapeutic vaccine designed for the treatment of diseases caused by the human papillomavirus (HPV), one of the most common sexually transmitted diseases in the world. An estimated 80% of sexually active men and women are infected by genital HPV at some point in their lives. Approximately 5.5 million new sexually transmitted HPV infections are reported in the U.S. each year. At least 20 million people in the U.S. are already infected. HPV infection can result in diseases including internal and external genital warts and precancerous conditions, such as cervical and anal dysplasia. Precancerous HPV-related conditions can progress into life-threatening diseases, including cervical, anal, and head and neck cancers.
This page has been viewed 252 times since April 2007, the link to the organisation's website has been followed 41 times Recent Search Terms used to find this page: nventa genital warts | Nventa Victoria BC | nventa download | Nventa Biopharmaceuticals VIctoria BC | Nventa | hpv 6 11 therapeutic warts OR ian fraser OR phase two therapeutic vaccine -cancer | when was nventa biopharmaceuticals established | nventa | nventa biopharmaceuticals bc | Nventa Biopharmaceuticals Corporation victoria | . Search for more companies in San Diego Search for more companies in California This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified. BioPortfolio search results for Nventa Biopharmaceuticals Corporation | ||||||||||||||||||||||||||||||||||||||||
|
|